Mitochondrial Cardiolipin-Targeted Tetrapeptide, SS-31, Exerts Neuroprotective Effects Within In Vitro and In Vivo...

Area of Science:

• Neuroscience
• Biochemistry
• Mitochondrial Biology

Background:

• Spinal cord injury (SCI) causes significant motor and sensory deficits with limited treatment options.
• Cardiolipin (CL), a mitochondrial phospholipid, is crucial for cellular energy and survival.
• CL alterations are implicated in SCI's secondary damage, but mechanisms are unclear.

Purpose of the Study:

• To investigate the protective effects of SS-31 against SCI-induced CL alterations, neuronal death, and functional deficits.
• To explore the role of CL in SCI pathogenesis and its potential as a therapeutic target.

Main Methods:

• In vitro studies used primary spinal cord neurons treated with rotenone or glutamate excitotoxicity.
• In vivo studies utilized a mouse model of contusive SCI.
• Methods included lipidomics, histology, cell death assays, neurite analysis, and behavioral assessments.

Main Results:

• SS-31 reduced mitochondrial dysfunction and neuronal death in vitro.
• SS-31 attenuated SCI-induced CL reduction in mice in a dose-dependent manner.
• SS-31 improved behavioral recovery post-SCI but did not significantly reduce tissue damage.

Conclusions:

• CL alteration is a key factor in SCI pathogenesis in C57BL/6 mice.
• SS-31 demonstrates therapeutic potential by targeting CL changes and improving functional outcomes after SCI.
• CL represents a promising therapeutic target for mitigating secondary SCI damage.